

Special Issue

Type 2 Diabetes: Current Progress and Future Challenges

Message from the Guest Editor

In recent decades, type 2 diabetes treatment has undergone a major change, from a former "glucocentric" approach to the novel, comprehensive dual principle of simultaneous control of glycemia and cardiovascular risk. Modern therapeutic options with cardioprotective and renoprotective effects provide a step forward toward the achievement of effective treatment targets. Furthermore, it is of utmost importance to highlight obesity and insulin resistance as dominant factors in the origin and development of type 2 diabetes, as well as its complications. This is supported by the latest research on the remission of type 2 diabetes in individuals with a significant reduction in body weight who received novel antidiabetic medications. Finally, improving the prevention and treatment methods of type 2 diabetes is vastly needed, with an emphasis on raising the awareness of clinicians in terms of learning the up-to-date guidelines and therapeutic options, as a leading strategy for the mitigation of therapeutic inertia.

Guest Editor

Dr. Tomislav Kurevija

Department of Family Medicine, Faculty of Medicine, J. J. Strossmayer University of Osijek, Osijek, Croatia

Deadline for manuscript submissions

31 March 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/249980

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).